- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00979420
Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Study Design:
observational
Tipo di studio
Contatti e Sedi
Luoghi di studio
-
-
-
Aachen, Germania
- Boehringer Ingelheim Investigational Site 1
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 10
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 11
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 14
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 4
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 5
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 8
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 9
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 12
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 13
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 15
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 2
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 3
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 6
-
Berlin, Germania
- Boehringer Ingelheim Investigational Site 7
-
Bochum, Germania
- Boehringer Ingelheim Investigational Site 16
-
Bonn, Germania
- Boehringer Ingelheim Investigational Site 17
-
Bremen, Germania
- Boehringer Ingelheim Investigational Site 18
-
Dortmund, Germania
- Boehringer Ingelheim Investigational Site 19
-
Duisburg, Germania
- Boehringer Ingelheim Investigational Site 20
-
Düsseldorf, Germania
- Boehringer Ingelheim Investigational Site 21
-
Düsseldorf, Germania
- Boehringer Ingelheim Investigational Site 22
-
Düsseldorf, Germania
- Boehringer Ingelheim Investigational Site 23
-
Düsseldorf, Germania
- Boehringer Ingelheim Investigational Site 24
-
Frankfurt, Germania
- Boehringer Ingelheim Investigational Site 25
-
Frankfurt, Germania
- Boehringer Ingelheim Investigational Site 26
-
Frankfurt, Germania
- Boehringer Ingelheim Investigational Site 27
-
Freiburg, Germania
- Boehringer Ingelheim Investigational Site 28
-
Freiburg, Germania
- Boehringer Ingelheim Investigational Site 29
-
Freiburg, Germania
- Boehringer Ingelheim Investigational Site 30
-
Hamburg, Germania
- Boehringer Ingelheim Investigational Site 31
-
Hamburg, Germania
- Boehringer Ingelheim Investigational Site 32
-
Hamburg, Germania
- Boehringer Ingelheim Investigational Site 33
-
Hamburg, Germania
- Boehringer Ingelheim Investigational Site 34
-
Hamburg, Germania
- Boehringer Ingelheim Investigational Site 35
-
Hamburg, Germania
- Boehringer Ingelheim Investigational Site 36
-
Hannover, Germania
- Boehringer Ingelheim Investigational Site 37
-
Hannover, Germania
- Boehringer Ingelheim Investigational Site 38
-
Hannover, Germania
- Boehringer Ingelheim Investigational Site 39
-
Heidelberg, Germania
- Boehringer Ingelheim Investigational Site 40
-
Karlsruhe, Germania
- Boehringer Ingelheim Investigational Site 41
-
Koblenz, Germania
- Boehringer Ingelheim Investigational Site 42
-
Leipzig, Germania
- Boehringer Ingelheim Investigational Site 43
-
Mannheim, Germania
- Boehringer Ingelheim Investigational Site 44
-
Mannheim, Germania
- Boehringer Ingelheim Investigational Site 45
-
München, Germania
- Boehringer Ingelheim Investigational Site 46
-
München, Germania
- Boehringer Ingelheim Investigational Site 47
-
München, Germania
- Boehringer Ingelheim Investigational Site 48
-
München, Germania
- Boehringer Ingelheim Investigational Site 49
-
München, Germania
- Boehringer Ingelheim Investigational Site 50
-
Münster, Germania
- Boehringer Ingelheim Investigational Site 51
-
Münster, Germania
- Boehringer Ingelheim Investigational Site 52
-
Münster, Germania
- Boehringer Ingelheim Investigational Site 53
-
Oldenburg, Germania
- Boehringer Ingelheim Investigational Site 54
-
Osnabrück, Germania
- Boehringer Ingelheim Investigational Site 55
-
Saarbrücken, Germania
- Boehringer Ingelheim Investigational Site 56
-
Stuttgart, Germania
- Boehringer Ingelheim Investigational Site 57
-
Stuttgart, Germania
- Boehringer Ingelheim Investigational Site 58
-
Stuttgart, Germania
- Boehringer Ingelheim Investigational Site 59
-
Wuppertal, Germania
- Boehringer Ingelheim Investigational Site 60
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion criteria The inclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843)
Exclusion criteria The exclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Prospettive temporali: Retrospettiva
Coorti e interventi
Gruppo / Coorte |
---|
Trattamento dell'HIV
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in log10 Viral Load From Baseline to Last Visit
Lasso di tempo: Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Baseline is defined as the last documentation before start of therapy with Viramune.
The change from baseline reflects the last available visit viral load minus the baseline viral load.
|
Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Number of Participants With Viral Load <50 Copies/ml and >=50 Copies/ml at Last Visit
Lasso di tempo: Last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
|
Change in Absolute CD4 Lymphocytes (CD4+) Cells From Baseline to Last Visit
Lasso di tempo: Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Baseline is defined as the last documentation before start of therapy with Viramune.
The change from baseline reflects the last available number of CD4+ cells minus the baseline number of CD4+ cells.
|
Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Change in Absolute CD4 Lymphocytes (CD4+ Cells) From Baseline to Last Visit
Lasso di tempo: Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Baseline is defined as the last documentation before start of therapy with Viramune.
The change from baseline reflects the last available number of CD4+ cells minus the baseline number of CD4+ cells.
|
Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Patients With Laboratory Abnormalities for Cholesterol During Study (Worst Grade) by Division of AIDS (DAIDS) Grade
Lasso di tempo: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events ("DAIDS AE Grading Table") was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Low-density Lipoprotein (LDL) Cholesterol During Study (Worst Grade) by DAIDS Grade
Lasso di tempo: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Triglycerides During Study (Worst Grade) by DAIDS Grade
Lasso di tempo: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Blood Glucose During Study (Worst Grade) by DAIDS Grade
Lasso di tempo: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Alanine Aminotransferase (ALT) During Study (Worst Grade) by DAIDS Grade
Lasso di tempo: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Aspartate Aminotransferase (AST) During Study (Worst Grade) by DAIDS Grade
Lasso di tempo: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Creatinine During Study (Worst Grade) by DAIDS Grade
Lasso di tempo: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Number of Patients With Laboratory Abnormalities for Hemoglobin During Study (Worst Grade) by DAIDS Grade
Lasso di tempo: Up to 185 months
|
Duration of intake of Viramune ranges from 14 to 185 months.
The "DAIDS AE Grading Table" was used for grading the safety laboratory parameters.
Grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = potentially life-threatening.
|
Up to 185 months
|
Duration of Intake of Viramune
Lasso di tempo: End of treatment, up to 185 months
|
Duration of intake of Viramune
|
End of treatment, up to 185 months
|
History of Therapy With Antiretroviral Medication
Lasso di tempo: Baseline
|
Participants with a history of therapy with antiretroviral medication.
|
Baseline
|
Course of Absolute CD4+ Cell Count
Lasso di tempo: Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months
|
The course of absolute CD4+ cell count is presented as the absolute CD4+ cell count at last visit.
|
Baseline and last available visit. Duration of intake of Viramune ranges from 14 to 185 months
|
Number of Participants With Drug Related Adverse Events
Lasso di tempo: Up to 185 months
|
Number of participants with drug related Adverse Events (AEs)
|
Up to 185 months
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da lentivirus
- Infezioni da retroviridae
- Sindromi da deficit immunologico
- Malattie del sistema immunitario
- Infezioni da HIV
Altri numeri di identificazione dello studio
- 1100.1535
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezioni da HIV
-
University of MinnesotaRitiratoInfezioni da HIV | HIV/AIDS | HIV | AIDS | Problema di Aids/Hiv | AIDS e infezioniStati Uniti
-
Erasmus Medical CenterNon ancora reclutamentoInfezioni da HIV | HIV | Infezione da HIV-1 | Infezione da HIV IOlanda
-
Helios SaludViiV HealthcareSconosciutoHIV | Infezione da HIV-1Argentina
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement; Centre Pasteur du Cameroun e altri collaboratoriSconosciutoHIV | Bambini non infetti da HIV | Bambini esposti all'HIVCamerun
-
University of MinnesotaCompletatoInfezioni da HIV | HIV | ImmunodeficienzaStati Uniti
-
Midway Specialty Care CenterNon ancora reclutamentoInfezioni da HIV | HIV | Infezione da HIV-1Stati Uniti
-
Allegheny Singer Research Institute (also known...Attivo, non reclutanteInfezioni da HIV | Infezione da HIV-1 | Infezione da HIV IStati Uniti
-
University of California, DavisCompletato
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completato
-
University of ZimbabweCompletato